BlueCross BlueShield TEC Not Impressed With ECP Therapy Evidence
This article was originally published in The Gray Sheet
Executive Summary
A BlueCross BlueShield Technology Evaluation Center analysis of external counterpulsation therapy builds on a recent CMS proposal intimating that the treatment is not likely to get reimbursement for additional cardiac conditions anytime soon
You may also be interested in...
CMS Proposes Not To Expand ECP Coverage, But Vasomedical Stays Hopeful
Vasomedical is counting on an impending journal publication to alter CMS' proposed decision not to expand coverage of external counterpulsation therapy for treating additional cardiac conditions
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.